Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate Cancer

Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 Feb 2003Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate Cancer GURAM KARAZANASHVILI and PER-ANDERS ABRAHAMSSON GURAM KARAZANASHVILIGURAM KARAZANASHVILI More articles by this author and PER-ANDERS ABRAHAMSSONPER-ANDERS ABRAHAMSSON More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)63932-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Several tumor markers have recently been applied for prostate cancer screening. We analyze the effectiveness of prostate specific antigen (PSA), age specific PSA, PSA velocity, volume adjusted PSA densities, change in PSA level following antibacterial therapy, free-to-total PSA ratio, α1-antichymotrypsin bound PSA, α2-macroglobulin bound PSA, α1-protease inhibitor bound PSA and human glandular kallikrein 2 in detecting prostate cancer. Materials and Methods: We conducted a review of the literature between September 2000 and February 2001. A total of 7,250 abstracts and articles published during the previous 12 years were retrieved from MEDLINE using the key words PSA and human glandular kallikrein 2. Of these reports 135 are included in this review. Results: We analyzed and systematized data from studies regarding the effectiveness of PSA and human glandular kallikrein 2 and their derivatives in the detection of prostate cancer. Conclusions: Improvement in the specificity and sensitivity of PSA is imperative. Free-to-total PSA ratio, transition zone PSA density and change in PSA level increase the specificity of PSA to some extent. Protocols investigating the effectiveness of different combinations of these 3 measurements seem necessary for improving the effectiveness of prostate cancer screening among men within the diagnostic “gray zone.” PSA velocity, age adjusted PSA levels and PSA density might be used in limited cases. α1-Antichymotrypsin, α2-macroglobulin and α1-protease inhibitor bound PSA, and human glandular kallikrein 2 are promising experimental methods. References 1 : The World Health Report.. http://www.who.org/whr. 1999. Google Scholar 2 : World Health Report.. http://www.who.org/whr. 2000. Google Scholar 3 : Screening for prostate cancer. Semin Surg Oncol2000; 18: 29. Google Scholar 4 : Early Detection and screening. In: Proceedings of the 2nd International Consultation on Prostate Cancer. Edited by . Paris, France: Health Publication Ltd.1999. June 27–29. Google Scholar 5 : Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am1997; 24: 353. Google Scholar 6 : Screening, early detection, and treatment of prostate cancer: a European view. Urology1995; 46: 62. Google Scholar 7 : A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest1985; 76: 1899. Crossref, Medline, Google Scholar 8 : Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem1990; 194: 755. Crossref, Medline, Google Scholar 9 : Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl1995; 16: 491. Google Scholar 10 : Three predominant proteins secreted by the human prostate gland. Prostate1988; 12: 29. Google Scholar 11 : Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem1991; 37: 1618. Crossref, Medline, Google Scholar 12 : A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res1991; 51: 222. Medline, Google Scholar 13 : Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol1993; 150: 100. Abstract, Google Scholar 14 : Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol1995; 154: 1090. Link, Google Scholar 15 : Problems in the determination of prostate specific antigen. Eur J Clin Chem Clin Biochem1996; 34: 735. Google Scholar 16 : Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med1987; 317: 909. Crossref, Medline, Google Scholar 17 : Prostate-specific antigen, clinical use and staging: an overview. Br J Urol1997; 79: 53. Google Scholar 18 : Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem1994; 220: 45. Crossref, Medline, Google Scholar 19 : A prostate antigen in sera of prostate cancer patients. Cancer Res1980; 40: 2428. Google Scholar 20 : Use of human prostate-specific antigen in monitoring of prostate cancer. Cancer Res1981; 41: 3874. Google Scholar 21 : Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: early detection strategies. Urology1995; 46: 125. Google Scholar 22 : Prostate serum markers. In: Proceedings of the 2nd International Consultation on Prostate Cancer. Edited by . Paris, France: Health Publication Ltd.1999. June 27–29. Google Scholar 23 : Prostate specific antigen—a screening test for prostatic cancer?. Br J Urol1989; 64: 504. Google Scholar 24 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991; 324: 1156. Crossref, Medline, Google Scholar 25 : The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer1991; 68: 2060. Google Scholar 26 : Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol1992; 147: 846. part 2. Link, Google Scholar 27 : Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol1990; 143: 1146. Link, Google Scholar 28 : Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate1999; 38: 296. Google Scholar 29 : Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol1994; 152: 1520. Link, Google Scholar 30 : Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol1994; 151: 1283. Link, Google Scholar 31 : Progress in standardization and quality assessment of free PSA (Prostate Specific Antigen), total PSA, and complexed PSA immunoassays. In: Proceedings of the 2nd International Consultation on Prostate Cancer. Edited by . Paris, France: Health Publication Ltd.1999. June 27–29. Google Scholar 32 : The clinical impact of different assays for prostate specific antigen. BJU Int2000; 86: 590. Crossref, Medline, Google Scholar 33 : Prostate-specific antigen. Semin Surg Oncol2000; 18: 3. Google Scholar 34 : Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol1999; 162: 293. Link, Google Scholar 35 : Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol1995; 153: 111. Link, Google Scholar 36 : Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol1995; 154: 407. Link, Google Scholar 37 : Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol1997; 157: 1301. Link, Google Scholar 38 : Screening for prostatic carcinoma with prostate specific antigen. J Urol, part 21992; 147: 841. Abstract, Google Scholar 39 : The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer1991; 67: 2949. Google Scholar 40 : Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J1994; 87: 720. Google Scholar 41 : Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA1993; 270: 948. Crossref, Medline, Google Scholar 42 : Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA1997; 277: 1452. Crossref, Medline, Google Scholar 43 : Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology1999; 54: 220. Google Scholar 44 : PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology1999; 54: 517. Google Scholar 45 : The incidence of prostate cancer in the PSA reflex range of 2.5 and 4.0 ng/ml. J Urol2000; 163: 88. abstract 386. Google Scholar 46 : Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet1994; 344: 1594. Google Scholar 47 : A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA1995; 273: 289. Crossref, Medline, Google Scholar 48 : Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA1996; 276: 1309. Crossref, Medline, Google Scholar 49 : Prostate cancer detection at low prostate specific antigen. J Urol2000; 163: 806. Link, Google Scholar 50 : Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer2000; 36: 1322. Google Scholar 51 : Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am1993; 20: 671. Google Scholar 52 : Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol1993; 150: 1837. Link, Google Scholar 53 : The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology1995; 46: 779. Google Scholar 54 : Derivation and application of upper limits for prostate specific antigen in men aged 50–74 years with no clinical evidence of prostatic carcinoma. Br J Urol1995; 76: 346. Google Scholar 55 : Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology1996; 48: 234. Google Scholar 56 : Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med1996; 335: 304. Google Scholar 57 : Age-specific reference values for serum prostate-specific antigen in a community-based population of healthy Swedish men. Scand J Clin Lab Invest1997; 57: 225. Google Scholar 58 : The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol1998; 82: 231. Google Scholar 59 : Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology1999; 54: 1022. Google Scholar 60 : Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology2000; 56: 278. Google Scholar 61 : Age-specific reference ranges for serum prostate-specific antigen. Urology1995; 46: 54. Google Scholar 62 : Potential effects of age-specific reference ranges for serum prostate-specific antigen. Eur Urol1995; 27: 182. Google Scholar 63 : Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology2000; 56: 255. Crossref, Medline, Google Scholar 64 : Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist. Urol Int2000; 64: 18. Google Scholar 65 : Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am1997; 24: 339. Google Scholar 66 : The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol1995; 153: 1160. Link, Google Scholar 67 : Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol1996; 155: 1336. Link, Google Scholar 68 : Age specific prostate specific antigen reference ranges: population specific. J Urol1998; 159: 444. Link, Google Scholar 69 : Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA1992; 267: 2215. Crossref, Medline, Google Scholar 70 : Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res1992; 52: 3323. Google Scholar 71 : Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology1995; 45: 591. Google Scholar 72 : Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am1997; 24: 333. Google Scholar 73 : Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol1994; 152: 1163. Abstract, Google Scholar 74 : Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol1999; 162: 1311. Abstract, Google Scholar 75 : Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems. Urol Int1998; 60: 25. Google Scholar 76 : Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol2000; 163: 158. Link, Google Scholar 77 : Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol2000; 163: 813. Link, Google Scholar 78 : Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol, part 21992; 147: 815. Abstract, Google Scholar 79 : Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology1994; 43: 601. Google Scholar 80 : Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer1997; 79: 1969. Google Scholar 81 : Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J Urol1997; 158: 2193. Link, Google Scholar 82 : Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer2000; 89: 842. Crossref, Medline, Google Scholar 83 : Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma. J Urol1998; 160: 77. Link, Google Scholar 84 : Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol1997; 157: 1315. Link, Google Scholar 85 : Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml. J Urol1997; 158: 502. Link, Google Scholar 86 : Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in Japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol1999; 29: 617. Google Scholar 87 : Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol1998; 160: 411. Link, Google Scholar 88 : Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer1997; 80: 1818. Google Scholar 89 : Does prostate-specific antigen density alter decision making on biopsy?. Eur Urol1996; 29: 10. Google Scholar 90 : The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. Eur Urol1996; 29: 189. Google Scholar 91 : Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: a cooperative study. Jpn J Clin Oncol1998; 28: 661. Google Scholar 92 : Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis1998; 1: 197. Google Scholar 93 : Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies. Urology1998; 52: 479. Crossref, Medline, Google Scholar 94 : Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. Urology1999; 53: 736. Google Scholar 95 : Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?. Urology2000; 55: 710. Google Scholar 96 : Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. Urology2000; 55: 909. Google Scholar 97 : Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol1997; 158: 505. Link, Google Scholar 98 : Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology1997; 50: 66. Google Scholar 99 : Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol2000; 163: 1144. Link, Google Scholar 100 : Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate1994; 25: 91. Crossref, Medline, Google Scholar 101 : Prostatic specific antigen and benign prostatic hyperplasia. Scand J Urol Nephrol1996; 30: 299. Google Scholar 102 : Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol2000; 37: 537. Crossref, Medline, Google Scholar 103 : Impact of prostate benign hyperplasia and prostatic inflammation on the increase of prostate specific antigen levels. Actas Urol Esp1997; 21: 100. Google Scholar 104 : Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol2000; 37: 404. Crossref, Medline, Google Scholar 105 : Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int1999; 84: 976. Google Scholar 106 : Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology2000; 55: 892. Google Scholar 107 : Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology1989; 33: 465. Crossref, Medline, Google Scholar 108 : Prostate-specific antigen levels in acute and chronic bacterial prostatitis. Hinyokika Kiyo1993; 39: 445. Google Scholar 109 : Prostate specific antigen (PSA) value change after the antibacterial therapy for prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4–10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol2001; 39: 538. Google Scholar 110 : The use of percent free PSA for early detection of prostate cancer. J Androl1999; 20: 449. Google Scholar 111 : Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J Urol1998; 160: 426. Link, Google Scholar 112 : Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer1992; 70: 230. Google Scholar 113 : Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol2000; 38: 380. Google Scholar 114 : Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem1998; 44: 1216. Google Scholar 115 : Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol2000; 163: 1476. Link, Google Scholar 116 : Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology2000; 55: 700. Crossref, Medline, Google Scholar 117 : Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology1999; 54: 225. Google Scholar 118 : Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology1999; 53: 1160. Google Scholar 119 : Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer. Eur Urol2000; 38: 85. Google Scholar 120 : Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem1999; 45: 814. Google Scholar 121 : Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem1998; 44: 2471. Google Scholar 122 : Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology2000; 56: 267. Google Scholar 123 : Prostate-specific antigen: molecular forms and the human kallikrein gene family. Br J Urol1997; 79: 44. Google Scholar 124 : Primary structure of a human glandular kallikrein gene. DNA1987; 6: 429. Crossref, Medline, Google Scholar 125 : Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun1995; 213: 888. Google Scholar 126 : Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem1996; 42: 1034. Google Scholar 127 : Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology1999; 53: 939. Crossref, Medline, Google Scholar 128 : Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol1997; 150: 455. Google Scholar 129 : Human glandular kallikrein 2 (hK2) in prostate cancer. Clinical and methodological studies. Lund University Dissertation Abstracts. Malmo, Sweden: Lund University2000. Google Scholar 130 : In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL. Urology1998; 52: 360. Google Scholar 131 : The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer1998; 83: 2540. Google Scholar 132 : Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology1999; 54: 839. Crossref, Medline, Google Scholar 133 : Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology2000; 55: 694. Google Scholar 134 : Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J Urol1998; 160: 2081. Link, Google Scholar 135 : Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction. Tech Urol1999; 5: 71. Google Scholar From the Department of Urology, Tbilisi State Medical University, Tbilisi, Georgia, and Departments of Urology, Malmö and Lund University Hospitals, Lund University, Lund, Sweden© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byRoobol M, Schröder F, Crawford E, Freedland S, Sartor A, Fleshner N and Andriole G (2009) A Framework for the Identification of Men at Increased Risk for Prostate CancerJournal of Urology, VOL. 182, NO. 5, (2112-2122), Online publication date: 1-Nov-2009. Volume 169Issue 2February 2003Page: 445-457 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostateprostatic neoplasmsprostate-specific antigenprostatitiskallikreinsMetricsAuthor Information GURAM KARAZANASHVILI More articles by this author PER-ANDERS ABRAHAMSSON More articles by this author Expand All Advertisement PDF downloadLoading ...